Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 25 MAY 1995

Pharmaceuticals - Belgian Pricing Regulations for Reimbursable Pharmaceutical Pr

Linklaters De Bandt
Explore more from Linklaters De Bandt

BelgiumEnvironment
The pharmaceuticals price freeze which lasted for one and a half years has been lifted on January 1, 1994. Since then, many pharmaceutical companies have requested a price increase for their products to the competent ministry.

Price setting for newly registered reimbursable prescription pharmaceutical products or price increases for existing products are determined pursuant to the Ministerial Decree of December 29, 1989 enacted in application of Title VI of the Law of December 22, 1989.

This regulation applies to all medicinal products, as defined in the Law of March 25, 1964, which qualify for the reimbursement in accordance with the Law of August 9, 1963, as well as to certain implants, as listed in the above Decree.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

EU’s CBAM Downstream Extension And Anti-Circumvention Amendments: The Road To Trilogue

The European Union's Carbon Border Adjustment Mechanism is undergoing critical legislative refinement as the Commission, Council, and Parliament have each established distinct positions on extending CBAM to downstream goods and strengthening anti-circumvention measures. With trilogue negotiations now underway and the first political trilogue scheduled for October 2026, significant divergences remain between the institutions on scope, exemptions, and enforcement mechanisms that will shape the final framework
European UnionEnvironment
Mayer Brown
Mayer Brown
Article

International Carbon Credits Under The Proposed EU ETS Revision And CBAM Implementing Regulations

The European Commission's proposal to revise the EU Emission Trading System introduces a significant new element: the potential purchase of up to 260 million international carbon credits. This development, alongside parallel provisions in the Carbon Border Adjustment Mechanism, signals a cautious but meaningful shift in how the EU approaches international carbon credits. Understanding these distinct treatment mechanisms has critical implications for ETS-covered operators, EU importers, and international tra
BelgiumEnvironment
A&O Shearman
A&O Shearman
Article

The EU's 2040 Climate Target: The Next Phase Of European Climate Governance

The European Union has codified a legally binding 90% net reduction in greenhouse gas emissions by 2040, fundamentally reshaping decarbonization trajectories, carbon market architecture, and industrial transition strategies. This intermediate climate target introduces a calibrated flexibility mechanism permitting limited use of high-quality international carbon credits while establishing distinct accounting tracks for domestic permanent removals and cross-border mitigation, creating significant implications
European UnionEnvironment
A&O Shearman
A&O Shearman
Article

Reforming The Market Stability Reserve: The 2026 Reform Proposals And The Road To The Trilogues

The European Commission's 2026 proposals to reform the Market Stability Reserve represent a fundamental shift in EU carbon policy, transforming what began as a technical mechanism to address allowance surplus into a multifaceted instrument balancing climate ambition, industrial competitiveness, and geopolitical concerns. This analysis traces the MSR's evolution from the 2010s crisis through successive amendments, examining how the cessation of invalidation and recalibrated parameters interact with broader i
European UnionEnvironment
A&O Shearman
A&O Shearman